SequelSEC

FEMASYS INC FEMY

Surgical & Medical Instruments & Apparatus · CIK 0001339005 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$2.30M
Fiscal year ended 2026-06-30
Operating income
-$17.57M
Fiscal year ended 2026-06-30
Free cash flow
-$18.07M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$29.87MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.49Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue13.0×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity5.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue22.9%92th
FCF margin-837.9%12th
Operating margin-767.0%12th
Net margin-812.3%12th
R&D / revenue330.4%87th
Revenue YoY growth40.8%82th
SBC / revenue34.5%82th
Current ratio4.53x70th
Gross margin62.0%50th

FEMASYS INC (FEMY) reported revenue of $2.30M and net income of -$11.77M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from FEMASYS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

FEMASYS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$2.30M
Cost of revenue$898.00K
Gross profit$1.40M
Operating income-$17.57M
Net income-$11.77M
Research & development$6.45M
Weighted-average diluted sharesUnavailable
Pretax income-$11.76M
Income tax expense$6.35K
Diluted EPSUnavailable
Selling, general & administrative$12.18M
General & administrative$7.02M
Selling & marketing$5.16M

Balance

FEMASYS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$1.44M
Total assets$12.29M
Current assets$8.33M
Total liabilities$8.26M
Current liabilities$3.89M
Total equity incl. NCI$4.03M
Temporary (mezzanine) equityUnavailable
Inventory$6.19M
Accounts receivable$151.05K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$2.34M

Cash flow

FEMASYS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$17.65M
Capital expenditures$422.71K
Investing cash flow-$537.85K
Financing cash flow$16.42M
Net change in cashUnavailable
Stock-based compensation$603.36K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$335.98K

Derived

FEMASYS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$18.07M
Gross margin60.9%
Operating margin-763.9%
FCF margin-786.0%
SBC / revenue26.2%
Current ratio2.14x
Revenue YoY growth21.9%
Net margin-511.8%
R&D / revenue280.5%
CapEx / revenue18.4%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open FEMY in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.